Unknown

Dataset Information

0

Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.


ABSTRACT:

Purpose

Intraventricular compartmental radioimmunotherapy (cRIT) with 131-I-omburtamab is a potential therapy for recurrent primary brain tumors that can seed the thecal space. These patients often previously received external beam radiotherapy (EBRT) to a portion or full craniospinal axis (CSI) as part of upfront therapy. Little is known regarding outcomes after re-irradiation as part of multimodality therapy including cRIT. This study evaluates predictors of response, patterns of failure, and radiologic events after cRIT.

Methods

Patients with recurrent medulloblastoma or ependymoma who received 131-I-omburtamab on a prospective clinical trial were included. Extent of disease at cRIT initiation (no evidence of disease [NED] vs measurable disease [MD]) was assessed as associated with progression-free (PFS) and overall survival (OS) by Kaplan-Meier analysis.

Results

All 27 patients (20 medulloblastoma, 7 ependymoma) had EBRT preceding cRIT: most (22, 81%) included CSI (median dose 2340 cGy, boost to 5400 cGy). Twelve (44%) also received EBRT at relapse as bridging to cRIT. There were no cases of radionecrosis. At cRIT initiation, 11 (55%) medulloblastoma and 3 (43%) ependymoma patients were NED, associated with improved PFS (p = 0.002) and OS (p = 0.048) in medulloblastoma. Most relapses were multifocal. With medium follow-up of 3.0 years (95% confidence interval, 1.8-7.4), 6 patients remain alive with NED.

Conclusion

For patients with medulloblastoma, remission at time of cRIT was associated with significantly improved survival outcomes. Relapses are often multifocal, particularly in the setting of measurable disease at cRIT initiation. EBRT is a promising tool to achieve NED status at cRIT initiation, with no cases of radiation necrosis.

SUBMITTER: Tringale KR 

PROVIDER: S-EPMC10050019 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.

Tringale Kathryn R KR   Wolden Suzanne L SL   Karajannis Matthias M   Haque Sofia S   Pasquini Luca L   Yildirim Onur O   Rosenblum Marc M   Benhamida Jamal K JK   Cheung Nai-Kong NK   Souweidane Mark M   Basu Ellen M EM   Pandit-Taskar Neeta N   Zanzonico Pat B PB   Humm John L JL   Kramer Kim K  

Journal of neuro-oncology 20230228 1


<h4>Purpose</h4>Intraventricular compartmental radioimmunotherapy (cRIT) with 131-I-omburtamab is a potential therapy for recurrent primary brain tumors that can seed the thecal space. These patients often previously received external beam radiotherapy (EBRT) to a portion or full craniospinal axis (CSI) as part of upfront therapy. Little is known regarding outcomes after re-irradiation as part of multimodality therapy including cRIT. This study evaluates predictors of response, patterns of failu  ...[more]

Similar Datasets

| S-EPMC9655863 | biostudies-literature
| S-EPMC7594549 | biostudies-literature
| S-EPMC6692907 | biostudies-literature
| S-EPMC2772031 | biostudies-literature
2022-09-07 | PXD036034 | Pride
| S-EPMC6223284 | biostudies-literature
| S-EPMC5636618 | biostudies-literature
| S-EPMC7969770 | biostudies-literature
| S-EPMC7807732 | biostudies-literature
| S-EPMC9519775 | biostudies-literature